
Results
9
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
9 companies
Johnson & Johnson
Market Cap: US$497.9b
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
JNJ
US$207.56
7D
2.5%
1Y
33.6%
Merck
Market Cap: US$262.3b
Operates as a healthcare company worldwide.
MRK
US$104.63
7D
10.1%
1Y
1.5%
Exelixis
Market Cap: US$11.6b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$44.21
7D
4.9%
1Y
23.0%
ADMA Biologics
Market Cap: US$4.6b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$19.14
7D
20.0%
1Y
-12.3%
CorMedix
Market Cap: US$740.6m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$9.65
7D
-3.8%
1Y
-3.3%
SIGA Technologies
Market Cap: US$426.1m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.04
7D
2.2%
1Y
-17.9%
Abeona Therapeutics
Market Cap: US$264.5m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$5.15
7D
22.6%
1Y
-19.7%
Puma Biotechnology
Market Cap: US$249.4m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$5.05
7D
3.4%
1Y
56.3%
BioStem Technologies
Market Cap: US$68.8m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$4.83
7D
28.8%
1Y
-64.2%